The global fexofenadine HCL market is expected to grow at a considerable CAGR during the forecast years. Fexofenadine HCL is an antihistamine drug used for the treatments of patients suffering from various allergies including seasonal allergic rhinitis and urticaria (Hives). The fexofenadine HCL comes in two forms, which include tablets for adults and oral suspension for children. The growth of the global fexofenadine HCl market is due to increased demand for fexofenadine HCL as the number of patients suffering from seasonal allergic rhinitis is increasing due to the changing environment. Seasonal allergic rhinitis is the condition in which a patient faces allergic infection due to a change of season once or year-round. Allergic rhinitis can cause various allergic symptoms such as runny or stuffy nose, watery or itchy red eyes. Antihistamine drugs including fexofenadine HCL are used for the treatment of such symptoms. For instance, in June 2021, News Medicine & Lifesciences published a Consumer Medicine Information (CMI) about “Telfast”. Telfast is the antihistamine tablet with fexofenadine HCL as the active ingredient, which can be used for the treatment of symptoms of seasonal allergic realities in children aged more than 12 years.

Impact of COVID-19 on Global Fexofenadine HCL Market

COVID-19 has impacted the global economy due to a slowdown in the manufacturing of various industries. Healthcare came under the essential services so the manufacturing of Fexofenadine HCL was persistent throughout the pandemic. The demand for Fexofenadine HCL was persistent as the patients suffering from seasonal allergic rhinitis were increasing due to changing seasons.

Segmental Outlook

The global Fexofenadine HCL market is segmented based on the application and dosage form. Based on application, the market is sub-segmented into seasonal allergic rhinitis and urticaria. Based on the dosage form, the market is sub-segmented into tablets and oral suspension. Among these, the application of fexofenadine HCL in the urticaria segment is expected to hold the prominent share in the global fexofenadine HCL market due to increasing patients of urticaria.

Global Fexofenadine HCL Market by Dosage Form, 2021(%)

The Tablets Segment is Anticipated to Hold a Major Share in the Global Fexofenadine HCL market.

The Fexofenadine HCL tablets segment is expected to hold the major share in the global Fexofenadine HCL market during the forecast year as tablets are the initial form for the treatment of any allergy. The tablets can be taken by the majority of patients except those facing difficulties in swallowing tablets or babies. Tablets are a very convenient form for taking medicines while traveling and come with various benefits. The benefit of tablets includes longer shelf life in medical stores, and the ability to accommodate more amount of active ingredients. Furthermore, tablets also are an easily transportable form of medicine for distribution across the globe.

Regional Outlooks

The global Fexofenadine HCL market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North American region is expected to hold the major share in the global Fexofenadine HCL market due to the increasing number of patients suffering from seasonal allergic rhinitis due to changing weather conditions, and the presence of several key players in the region.

Global Fexofenadine HCL Market Growth by Region, 2022-2028

The Asia Pacific Region is Expected to Grow at a Significant CAGR among the Global Fexofenadine HCL Market During Forecast Year.

The Asia Pacific regional fexofenadine HCL market is anticipated to grow at a significant CAGR during the forecast year due to the increasing number of patients suffering from season allergic rhinitis and urticaria as the standards and eating habits of people are changing. In addition, the high capacity of manufacturing in the emerging economies such as India in the Asia Pacific region, from where the distribution of Fexofenadine HCL is expected to increase is expected to propel the growth of the Asia Pacific regional Fexofenadine HCL market.

Market Players Outlook

The major companies serving the global fexofenadine HCL market include AstraZeneca group Co., Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Novartis International AG, Methpharm, Inc., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, fundings, and new product launches. For instance, in July 2019, Dr. Reddy’s Lab Ltd. launched fexofenadine 60mg extended-release tablets. These tablets are available over the counter and equivalent to Allegra-D 12 HR (USFDA). The fexofenadine HCL 60mg extended-release tablets can be used to treat allergic symptoms such as runny nose, itchy eyes, watery eyes, sneezing, and itching of the nose or throat.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Fexofenadine HCL market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market